The University of Texas M. D. Anderson Cancer Center, Houston, USA.
Adv Drug Deliv Rev. 2010 Sep 30;62(12):1213-6. doi: 10.1016/j.addr.2010.09.014. Epub 2010 Oct 4.
Advances in the technology for phage display in vivo have set the stage for a new ligand-directed pharmacology with broad implications for both treatment and molecular imaging of patients, and for the elucidation of molecular mechanisms of action, particularly in carcinogenesis. This technology identifies specific molecular complexes, mainly small peptide and gene-based therapeutic and imaging agents, effective in experimental animals and patients. The unbiased identification of molecular targets on the surfaces of blood vessels and parenchymal cells in preselected specific organs and tissues raises the prospect of an increased understanding of animal and human cellular and vascular proteomics. In this review, we focus on the delivery of phage-based agents via stem and progenitor cells, important delivery vehicles contributing to the growing impact of phage display on modern medicine.
噬菌体展示技术的发展为配体导向的药理学开辟了新的前景，这对患者的治疗和分子成像具有广泛的意义，也有助于阐明作用的分子机制，特别是在肿瘤发生方面。该技术可鉴定在实验动物和患者中有效的特定分子复合物，主要是基于小肽和基因的治疗和成像剂。在预先选择的特定器官和组织中，对血管和实质细胞表面上的分子靶标的无偏鉴定提高了对动物和人类细胞和血管蛋白质组学的理解的可能性。在这篇综述中，我们重点介绍了基于噬菌体的制剂通过干细胞和祖细胞的递送来实现，这是重要的递药载体，有助于噬菌体展示对现代医学的日益增长的影响。
